Kah Lok Chan

Kah Lok Chan

Auto-generated profile, based on publicly available information

Kah Lok Chan

Peter MacCallum Cancer Centre, Melbourne, Australia

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2019 in Cancer Cell
Verified
Journal Article
Open access
MBMarian L. Burr
Marian L. Burr
CSChristina E. Sparbier
Christina E. Sparbier
KCKah Lok Chan
Kah Lok Chan
YCYih-Chih Chan
Yih-Chih Chan
AKAriena Kersbergen
Ariena Kersbergen
MDMark A. Dawson
Mark A. Dawson
Loss of MHC class I (MHC-I) antigen presentation in cancer cells can elicit immunotherapy resistance. A genome-wide CRISPR/Cas9 screen identified an evolutionarily conserved function of polycomb repressive complex 2 (PRC2) that mediates coordinated transcriptional silencing of the MHC-I antigen processing pathway (MHC-I APP), promoting evasion of T cell-mediated immunity. MHC-I APP gene promoters in MHC-I low cancers harbor bivalent activating H3K4me3 and repressive H3K27me3 histone modifications, silencing basal MHC-I expression and restricting cytokine-induced upregulation. Bivalent chromatin at MHC-I APP genes is a normal developmental process active in embryonic stem cells and maintained during neural progenitor differentiation. This physiological MHC-I silencing highlights a conserved mechanism by which cancers arising from these primitive tissues exploit PRC2 activity to enable immune evasion.

11 December 2019 in Nature
Verified
Journal Article
Closed access
LMLaura MacPherson
Laura MacPherson
JAJuliana Anokye
Juliana Anokye
MYMiriam M. Yeung
Miriam M. Yeung
ELEnid Y. N. Lam
Enid Y. N. Lam
YCYih-Chih Chan
Yih-Chih Chan
MDMark A. Dawson
Mark A. Dawson

1 December 2007 in Anesthesia & Analgesia
Verified
Journal Article
Closed access
KCKah-Lok Chan
Kah-Lok Chan
RSRobyn G. Summerhayes
Robyn G. Summerhayes
VIVera Ignjatovic
Vera Ignjatovic
SHStephen B. Horton
Stephen B. Horton
PMPaul Monagle
Paul Monagle
The hemostatic system of children changes with age and differs significantly from the hemostatic system of adults. Age-specific reference values are therefore required for most hemostatic variables. Thromboelastography (TEG®) is a point-of-care coagulation test that may provide superior evaluation and management of coagulopathies after cardiac surgery, when large-dose unfractionated heparin is administered for cardiopulmonary bypass. In this study, we established reference values for kaolin-activated TEG in healthy children, to facilitate accurate interpretation of pediatric TEG results. Kaolin-activated TEG was performed on 100 healthy children undergoing elective day surgery and 25 healthy adult volunteers. The following TEG variables were recorded: reaction time, coagulation time, α angle, maximum amplitude, percentage lysis 30 min after maximum amplitude was reached, and the coagulation index. Differences between age-groups were evaluated using analysis of variance. Age-specific reference values for kaolin-activated TEG in healthy children between 1 mo and 16 yr of age are presented. No significant differences between children and adults were observed. TEG results, from a particular clinical setting, must be compared to age-specific, as well as analyzer- and activator-specific, reference values to allow for correct interpretation of the results. Reference values provided here will be of use in acute clinical situations where a practical monitor of hemostasis is required.

1 August 2016 in Journal of Blood Medicine
Verified
Journal Article
Open access
PDF file
H. Miles PrinceH. Miles Prince
H. Miles Prince
KCKah-Lok Chan
Kah-Lok Chan
SLStephen Lade
Stephen Lade
SHSimon J Harrison
Simon J Harrison
Update and new approaches in the treatment of Castleman disease Kah-Lok Chan,1 Stephen Lade,2 H Miles Prince,1,3 Simon J Harrison1,3 1Department of Haematology, 2Department of Anatomical Pathology, Peter MacCallum Cancer Centre, 3Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, Australia First described 60 years ago, Castleman disease comprises a rare and heterogeneous cluster of disorders, characterized by lymphadenopathy with unique histological features and associated with cytokine-driven constitutional symptoms and biochemical disturbances. Although unicentric Castleman disease is curable with complete surgical excision, its multicentric counterpart is a considerable therapeutic challenge. The recent development of biological agents, particularly monoclonal antibodies to interleukin-6 and its receptor, allow for more targeted disease-specific intervention that promises improved response rates and more durable disease control; however, further work is required to fill knowledge gaps in terms of underlying pathophysiology and to facilitate alternative treatment options for refractory cases. Keywords: Castleman disease, angiofollicular lymph node hyperplasia, biologics, siltuximab, tocilizumab, rituximab

15 March 2013 in Neuro-Oncology
Verified
Journal Article
Open access
PDF file
GGGareth Peter Gregory
Gareth Peter Gregory
AAAshwini Arumugaswamy
Ashwini Arumugaswamy
TLTeresa Leung
Teresa Leung
KCKah-Lok Chan
Kah-Lok Chan
MAMelody Abikhair
Melody Abikhair
Stephen OpatStephen Opat
Stephen Opat
The optimal treatment strategy in patients with aggressive B cell central nervous system lymphoma suitable to receive intensive therapy is unknown. The benefit of incorporating rituximab in systemic therapy remains unclear. We performed a retrospective study examining the impact of rituximab in the context of concomitant therapies, including methotrexate, cytarabine, and radiotherapy, in patients treated with curative intent at 4 university teaching hospitals during 1996–2011. A retrospective study of CNS lymphoma cases treated at the participating institutions was performed in accordance with institutional ethical guidelines. Patients were included if they received a diagnosis of primary diffuse large B cell lymphoma of the CNS, were HIV negative, and were treated with curative intent. One hundred twenty patients aged 21–81 years were identified. Rituximab recipients and nonrecipients were similar, except for rituximab recipients being more likely to have received a diagnosis after 2004. The median follow-up of surviving patients was 30 months. The 5-year overall survival was 46%. Univariate analysis revealed age ≤60 years, ECOG performance status ≤1, normal lactate dehydrogenase, diagnosis after 2004, and treatment with cytarabine and rituximab as predictive of favorable overall survival. Multivariate analysis identified age to be an independent predictor of overall survival, with a trend toward improved survival from the other variables that were significant in univariate analyses. In this retrospective analysis, the addition of rituximab to high-dose methotrexate-based chemotherapy in patients with aggressive B cell CNS lymphoma was associated with improved overall survival. Further studies are underway to prospectively validate these findings.

12 January 2023 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
CSChristina E. Sparbier
Christina E. Sparbier
AGAndrea Gillespie
Andrea Gillespie
JGJuliana Gomez
Juliana Gomez
NKNishi Kumari
Nishi Kumari
AMAli Motazedian
Ali Motazedian
MDMark A. Dawson
Mark A. Dawson